(Q34291406)

1 August 2017

1 reference

title

Advances in systemic therapy for psoriasis (English)

1 reference

1 August 2017

1 reference

Mrowietz U

1

1 reference

1 August 2017

publication date

1 June 2001

1 reference

Clinical and Experimental Dermatology

1 August 2017

published in

1 reference

1 August 2017

volume

26

1 reference

1 August 2017

issue

4

1 reference

1 August 2017

page(s)

362-367

1 reference

Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2001.00835.X

Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2001.00835.X

Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2001.00835.X

Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2001.00835.X

Inhibition of dendritic cell differentiation by fumaric acid esters

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2001.00835.X

Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2001.00835.X

Chimaeric CD4 monoclonal antibody in treatment of generalised pustular psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2001.00835.X

Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2001.00835.X

Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2001.00835.X

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2001.00835.X

Treatment of psoriasis with interleukin-10

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2001.00835.X

Psoriasis vulgaris treated successfully with mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2001.00835.X

Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2001.00835.X

Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2001.00835.X

Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2001.00835.X

10.1046/J.1365-2230.2001.00835.X

21 January 2018

Identifiers

DOI

1 reference

1 August 2017

1 reference